Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02032875 · ClinicalTrials.gov registry record · Phase 3
Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
NCT02032875 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 116 participants.
The verdict
NCT02032875, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
Study Summary
This trial was open to participants who had received a liver transplant or had cirrhosis due to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were followed for 24 weeks post treatment. Under certain conditions, the treatment duration could have been extended for cirrhotic participants. The study tested the efficacy and safety of this combination for treatment of HCV in cirrhotic and post transplant patients.
Interventions
- DRUG Ribavirin
- DRUG Sofosbuvir
- DRUG Daclatasvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02032875
The ClinicalTrials.gov registry entry for NCT02032875 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT02032875 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02032875 about?
NCT02032875 is a clinical study titled "Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant". This trial was open to participants who had received a liver transplant or had cirrhosis due to chronic HCV. All subjects were treated with daclatasvir+sofosbuvir+ribavirin and were followed for 24 weeks post treatment. Under certain conditions, the treatment duration could have been extended for ci...
What is the current status of trial NCT02032875?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2014-03. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02032875?
The interventions under investigation include: Ribavirin (DRUG), Sofosbuvir (DRUG), Daclatasvir (DRUG).
Who is sponsoring clinical trial NCT02032875?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.